Everything below concerns thymosin beta-4. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-03-20. Where a claim depends on a specific study, the study is described rather than over-claimed.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilised powder | Sealed vial; reconstituted before laboratory use |
| Appearance | White to off-white solid | Visual descriptor used on certificates of analysis |
| Solubility class | Water-soluble | Dissolves in water and aqueous buffers |
| Reported mass, fragment | Near 889 Da | Value depends on the stated sequence |
| Reported mass, parent protein | Near 4963 Da | 43-residue thymosin beta-4 |
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
Researchers with the biotechnology company Rejuvenate Bio managed to extend the lifespans of elderly mice by 109%, reverse age-related frailty in the mice, and achieve signs of age reversal in human skin cells with gene therapy, employing partial cellular reprogramming.
variegation Variation or irregularity in a particular phenotype, especially a conspicuous visible trait such as color or pigmentation, occurring simultaneously in different parts of the same individual organism due to any of a variety of causes, such as X-inactivation, mitotic recombination, transposable element activity, position effects, or infection by pathogens.
=== 2025: Australian Open final, 500th win === Alongside Team Germany, Zverev failed to defend the United Cup after withdrawing from the event due to injury. Entering the 2025 Australian Open as the second seed for the first time in his career, Zverev began his tournament with a dominant victory over 2019 semifinalist Lucas Pouille in the first round. He reached his second consecutive and third overall semifinal at the Australian Open defeating Pedro Martínez, Jacob Fearnley, Ugo Humbert, and Tommy Paul. Against the 24-time major champion, Zverev won the 81-minute first set against Djokovic before the latter's retirement due to injury, advancing to his third major final. In the final, Zverev lost to defending champion Jannik Sinner in straight sets. Following his defeat to Sinner, a visibly distraught Zverev delivered an emotional speech during the trophy ceremony, stating, "I want to thank my team... I'm just not good enough. It's as simple as that." In the post-match press conference, he reflected on his career trajectory and the pressure of being a perennial contender without a Major title, reportedly remarking that he "didn't want to be the best player in history without a Grand Slam", expressing his desperation to finally break the barrier after losing his third major final. Over the next two months, Zverev made quarterfinals at the South American events he played in, Buenos Aires and Rio de Janeiro, losing to Argentines Francisco Cerundolo and Francisco Comesana, respectively.
Sources: en.wikipedia.org
=== Condensed matter and macromolecules === Metastable phases are common in condensed matter and crystallography. This is the case for anatase, a metastable polymorph of titanium dioxide, which despite commonly being the first phase to form in many synthesis processes due to its lower surface energy, is always metastable, with rutile being the most stable phase at all temperatures and pressures. As another example, diamond is a stable phase only at very high pressures, but is a metastable form of carbon at standard temperature and pressure. It can be converted to graphite (plus leftover kinetic energy), but only after overcoming an activation energy – an intervening hill. Martensite is a metastable phase used to control the hardness of most steel. Metastable polymorphs of silica are commonly observed. In some cases, such as in the allotropes of solid boron, acquiring a sample of the stable phase is difficult. The bonds between the building blocks of polymers such as DNA, RNA, and proteins are also metastable. Adenosine triphosphate (ATP) is a highly metastable molecule, colloquially described as being "full of energy" that can be used in many ways in biology. Generally speaking, emulsions/colloidal systems and glasses are metastable. The metastability of silica glass, for example, is characterised by lifetimes on the order of 1098 years (as compared with the lifetime of the universe, which is thought to be around 1.3787×1010 years). Sandpiles are one system which can exhibit metastability if a steep slope or tunnel is present. Sand grains form a pile due to friction.
== External links == Pathway at biocarta.com Nosek, Thomas M. "Section 6/6ch2/s6ch2_34". Essentials of Human Physiology. Archived from the original on 2016-03-24. Overview of all the structural information available in the PDB for UniProt: P01282 (VIP peptides) at the PDBe-KB.
=== Teflon (polytef) === This was the original material used as a bulking agent, first used to treat urinary incontinence in 1964, and then about 20 years later it was the first material used as a bulking agent to treat FI. Polytef paste is polytetrafluoroethylene, glycerin and polysorbide. The particles are mostly very small in size (4–40-μm). Research in animals has shown that these particles migrate and may be found in lymph nodes, lungs, kidneys, spleen and brain. If the material mostly migrates away, any benefit will be temporary, and there are safety concerns that it could lead to the formation of foreign body granulomas and the development of sarcoma.
Sources: en.wikipedia.org
2° being the center (Bolivia) weakened by the forces of both (Argentina and Peru)". The first indications of this policy for the domain of the South Pacific occurred in the Conquest of Chiloé. After the first Chilean attempt to annex the archipelago failed, Simón Bolívar (Peru's dictator at the time), eager to curry favor with the Peruvian elite, began to consider sending an expedition to bring it under the sovereignty of Lima, based on the uti possidetis iuris (because Chiloé was under the direct administration of the Viceroyalty of Peru, and then, to this republic corresponded the territory), before Spain negotiated and ceded the island potentially to the United Kingdom or France, powers that were known to be interested in that territory, or the Chilotas attempted an expedition to some region of the South Pacific. For the Chilean government, having Bolivarian troops to the south and north (in 1825, after the occupation of Upper Peru, the forces of Bolívar went on to seize all the territory north of the Loa) was considered a threat to their sovereignty. For the same reason, Bolívar's offer to form a joint expedition that would include 2,000 Colombian soldiers was rejected. Finally, the ruler of Colombia and Peru would demand that the Freire government end the threat that royalist Chiloé posed to South America or annex it to Peru (Bolivar was willing to renounce Peruvian claims to the territory to avoid strengthening Peru economically).
==== Pale or gray ==== Stool that is pale or grey may be caused by insufficient bile output due to conditions such as cholecystitis, gallstones, giardia parasitic infection, hepatitis, chronic pancreatitis, or cirrhosis. Bile pigments from the liver give stool its brownish color. If there is decreased bile output, stool is much lighter in color.
== Prognosis == Prognosis varies with the type of amyloidosis and the affected organ system. Prognosis for untreated AL cardiac amyloidosis is poor, with a median survival of six months. More specifically, AL amyloidosis can be classified as stage I, II or III based on cardiac biomarkers like Nt-proBNP and cardiac troponin. Survival diminishes with increasing stage, but recent advancements in treatments have improved median survival rates for stages I, II, and III, to 91.2, 60, and 7 months respectively. Outcomes in a person with AA amyloidosis depend on the underlying disease, organ(s) affected, and correlate with the concentration of serum amyloid A protein. People with ATTR, mutant ATTR and wild-type ATTR have a better prognosis when compared to people with AL and may survive for over a decade. Survival time is not associated with gender or age, however, some measures of reduced heart function are associated with a shorter survival time. Senile systemic amyloidosis was determined to be the primary cause of death for 70% of people over 110 who have been autopsied.
Protein–protein interactions regulate enzymatic activity, control progression through the cell cycle, and allow the assembly of large protein complexes that carry out many closely related reactions with a common biological function. Proteins can bind to, or be integrated into, cell membranes. The ability of binding partners to induce conformational changes in proteins allows the construction of enormously complex signaling networks. As interactions between proteins are reversible and depend heavily on the availability of different groups of partner proteins to form aggregates that are capable to carry out discrete sets of function, study of the interactions between specific proteins is a key to understand important aspects of cellular function, and ultimately the properties that distinguish particular cell types.
Sources: en.wikipedia.org
No. TB-500 is a trade-style label used for a synthetic peptide described as a fragment of thymosin beta-4, while thymosin beta-4 is the full 43-residue protein. The two differ in size and are not interchangeable terms in analytical work.
Naming for research peptides is not standardised, and suppliers sometimes apply the same label to different chain lengths. Certificates of analysis and mass data are the practical way to determine what a given lot contains.
The fragment commonly cited under this label is reported near 889 Da, and the parent protein near 4963 Da. Reported values shift with the exact sequence and with residual counter-ions or water in the sample.
Usually not, though usage overlaps. The label most often refers to a short acetylated fragment of the parent protein, while thymosin beta-4 itself is the full 43-residue molecule. Because suppliers vary, a sequence statement is needed to settle the question for any particular lot.